1. Equates to being at high risk for adverse cardiac events with continued medical therapy.

2. Supports consideration for LVAD use or transplant listing based on anticipated projected benefits and risks.

3. Prompts a trigger for an advanced HF cardiac therapy evaluation.


Session date: 
01/27/2017 - 12:00pm to 1:00pm CST
UCMC W-632
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Jerry D. Estep, MD